Article: Evaluating CCI of sterile vials using gas ingress
The article describes how CCI can be determined using Headspace gas ingress as a CCI test.
List view / Grid view
The article describes how CCI can be determined using Headspace gas ingress as a CCI test.
The solubility of a compound in organic solvents or water is equally important for screen design and later for process development.
Automated endotoxin testing is achieved in a compact platform, leveraging microfluidic liquid handling. QC labs simplify BET with easier, compliant assays using less LAL.
This article describes the effects of deep cold storage on the container closure integrity of sterile product vials.
This whitepaper discusses the analytical testing considerations for complex biological materials in ATMPs.
Improve and accelerate your crystallisation screening with the Crystal16 parallel crystalliser.
Save time with the feedback control option at the Crystal16 and the CrystalBreeder. Simplify crystallisation by automating your process.
Challenges and solutions to adopting MALDI technology for filamentous fungi ID with emphasis on sample preparation and database development.
The journey from large molecule to approved biotherapeutic is long, costly, complex, and fraught with risk – yet rewards for success are substantial.
This paper takes a closer look at plastic storage bags for bioprocesses focusing on a shift from multilayer to single-layer storage solutions.
A framework to enable a holistic approach to CCI that assures both primary packaging and process contribute to good CCI of sterile vial product.
Replacing traditional moisture analysis methods with a rapid, analytical and non-destructive method to improve the quality of freeze-dried product.
Product characterisation facilitates easier process design to ensure the biological drug attains critical product safety, purity, and potency.
iCON has improved delivery capacity by standardising the infrastructure for a flexible and readily available drug manufacturing facility.
iCON has improved delivery capacity by standardising the infrastructure for a flexible and readily available drug manufacturing facility.